Dual-specificity phosphatase 21 enhances the sensitivity of imatinib-resistant chronic myeloid leukemia cells to ponatinib through GATA-1-mediated erythroid differentiation
Authors:
- 18 March 2026
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 814, 153646
Abstract
No abstract availableKeywords
Funding Information
- Chi Mei Medical Center
This publication has 27 references indexed in Scilit:
- Management of chronic myeloid leukemia in 2025Cancer, 2025
- Chronic Myeloid LeukemiaJAMA, 2025
- Dual-specific phosphatase DUSP21 is a novel negative feedback regulator for STAT3Biochemical and Biophysical Research Communications, 2025
- Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019Cancer, 2023
- Dual-specificity MAP kinase phosphatases in health and diseaseBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2019
- A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cellsApoptosis, 2016
- RNA Interference Against Cancer/Testis Genes Identifies Dual Specificity Phosphatase 21 as a Potential Therapeutic Target in Human Hepatocellular CarcinomaHepatology, 2013
- Genetic Mechanisms of Chronic Myeloid Leukemia Blastic TransformationCurrent Hematologic Malignancy Reports, 2012
- Activin A induction of erythroid differentiation through MKK6‐p38α/p38β pathway is inhibited by follistatinJournal of Cellular Physiology, 2010
- c‐Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitorsJournal of Cellular Physiology, 2008